GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incanthera PLC (AQSE:INC) » Definitions » Common Stock

Incanthera (AQSE:INC) Common Stock : £1.56 Mil (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Incanthera Common Stock?

Incanthera's quarterly common stock stayed the same from Sep. 2022 (£1.53 Mil) to Mar. 2023 (£1.53 Mil) but then increased from Mar. 2023 (£1.53 Mil) to Sep. 2023 (£1.56 Mil).

Incanthera's annual common stock stayed the same from Mar. 2021 (£1.48 Mil) to Mar. 2022 (£1.48 Mil) but then increased from Mar. 2022 (£1.48 Mil) to Mar. 2023 (£1.53 Mil).


Incanthera Common Stock Historical Data

The historical data trend for Incanthera's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incanthera Common Stock Chart

Incanthera Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Common Stock
1.22 1.48 1.48 1.53

Incanthera Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Common Stock Get a 7-Day Free Trial 1.48 1.48 1.53 1.53 1.56

Incanthera Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Incanthera (AQSE:INC) Business Description

Traded in Other Exchanges
N/A
Address
76 King Street, Manchester, GBR, M2 4NH
Incanthera PLC is a specialist dermatology and oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops solutions to current clinical, commercially relevant unmet needs, utilising a new technology. The company's current products are Sol, EP0015, Equin and Duo-C. The company has one segment, namely the development of pharmaceutical products all within the United Kingdom.

Incanthera (AQSE:INC) Headlines

No Headlines